Please assess the completion status of the following clinical trial:

Trial Title: A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible for inclusion in this study have to fulfill all of the following criteria:~  1. Written informed consent must be obtained before any assessment is performed.~ 2. Patients who complete the treatment epoch in study CQGE031C2201 and complete at least Visit 203 (Week 32 of the follow-up epoch, ≥16 weeks after last injection) and present with active disease as defined by UAS7 ≥12.~ 3. Patients must not have any missing eDiary entries in the 7 days prior to Visit 301 (patients are allowed to repeat until this criterion is met).~ 4. Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules.~Exclusion Criteria:~Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria~* Evidence of parasitic infection~* Any other skin diseases than chronic spontaneous urticaria with chronic itching~* Contraindications to or hypersensitivity to fexofenadine, loratadine, cetirizine, or epinephrine~* History of anaphylaxis~* History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study~* History of hypersensitivity to any of the study drugs or its components of similar chemical classes~* Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ligelizumab (Type: EXPERIMENTAL): QGE031 240 mg s.c. q4w x 13 treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).